Researchers: A Surprising Link Between Autoimmune Diseases and Arteriosclerosis

Initial note. This article is an updated version of previously published content. The update follows scientific and informative criteria for clarity and verifiability. The information provided is for informational purposes only and does not replace medical advice.

IN BRIEF

• A well-established association exists between many autoimmune diseases and an increased risk of atherosclerosis; immune mechanisms, including plasmacytoid dendritic cells (PDCs) and type I interferons, may contribute to this relationship.
• Experiments in animal models show that the activation or presence of PDCs promotes pro-inflammatory processes in arterial plaques and can increase foam cell formation and endothelial damage.
• Evidence comes from experimental and observational studies: they indicate biological plausibility but do not prove that every single autoimmune disease directly causes atherosclerosis in every patient.
• Research suggests possible therapeutic targets in the interferon system and PDC activation pathways, but any clinical strategy requires specific clinical trials.

Abstract: what does science say?

The topic focuses on the correlation between certain autoimmune diseases and the increased prevalence of atherosclerosis observed in many clinical studies. Plasmacytoid dendritic cells (PDCs) are a distinct subpopulation of immune system cells known for their ability to produce large quantities of type I interferons. Experimental data from murine models and preclinical analyses show that auto-antigenic protein-DNA complexes, stimulation of specific toll-like receptors, and type I interferon production can promote inflammatory responses in the vascular wall, favoring macrophage accumulation, foam cell formation, and endothelial alterations that contribute to plaque progression. Available evidence includes experimental studies, clinical observations, and reviews; these support the biological plausibility of the link but do not universally establish a direct causal relationship for all clinical contexts. Questions remain regarding the relative contribution of different immune components, individual variations, and which targeted treatments can safely and effectively reduce cardiovascular risk.

What are plasmacytoid dendritic cells (PDCs)?

PDCs are a distinct subtype of dendritic cells characterized by their ability to rapidly produce large quantities of type I interferons in response to viral signals or nucleoprotein complexes. Under normal conditions, they act as sentinels of the innate response, but in autoimmune contexts, they can be activated by auto-antigens containing DNA or RNA or by nucleic acid-rich structures. This triggers the release of cytokines that modulate the activity of other immune cells and influence the behavior of macrophages and endothelial cells, central elements in the biology of atherosclerotic plaque [1].

Experimental evidence linking PDCs and atherosclerosis

Studies in animal models show that experimental activation of PDCs or their interaction with auto-antigenic protein-DNA complexes increases atherosclerotic plaque progression and the presence of foam cell macrophages in lesions [2]. In ApoE-/- mouse models, targeted depletion of PDCs reduces lesion formation, suggesting a pro-atherogenic role for this cell population in some experimental contexts [3]. Other work indicates that antigen presentation by PDCs on MHC II molecules can promote pro-inflammatory T cell responses that sustain local inflammation in the vascular wall [4]. These experimental data provide a mechanistic basis linking PDC activation to known processes of atherogenesis.

Type I interferons: mediation between autoimmunity and vascular damage

Type I interferons (including IFN-α and IFN-β) produced in large quantities by PDCs and other sources can have multiple effects on vascular biology. At the endothelial level, they promote dysfunction, alter nitric oxide release, and can impair vascular repair processes; at the macrophage level, they promote lipid accumulation and foam cell formation, and modulate T and B cell responses in the plaque [5][6]. In autoimmune diseases associated with an increased interferon "signature," these alterations constitute a plausible pathway linking systemic immune activation with accelerated vascular disease [5][7].

What this means in practice

For non-specialist readers: research indicates that immune mechanisms shared between certain autoimmune diseases and atherosclerosis may explain, at least in part, the increased cardiovascular risk observed in patients with these conditions. This does not mean that every person with an autoimmune disease will develop atherosclerosis: the risk is influenced by many factors — age, lipid profile, smoking, blood pressure, autoimmune disease control, obesity, genetics, and pharmacological treatment. The practical value of the research lies in clarifying possible biological targets for future interventions: for example, modulating the interferon pathway or PDC activation could theoretically reduce vascular inflammation. However, these strategies must be tested in controlled clinical trials to assess efficacy and safety. In the meantime, the recommended practical approach remains the integrated management of cardiovascular risk in people with autoimmune diseases: control of modifiable risk factors and collaboration between specialists (rheumatologists, cardiologists, general practitioners). The information provided here does not replace individual medical advice.

KEY POINTS TO REMEMBER

• Plasmacytoid dendritic cells are important producers of type I interferons and can contribute to local inflammatory processes in atherosclerotic plaque.
• Experimental studies in animals and preclinical analyses show that specific PDC activations increase plaque progression; experimental depletion of PDCs in some models reduces the disease.
• Over-activation of the interferon pathway (IFN-I) is a possible biological key explaining the association between certain autoimmune diseases and increased cardiovascular risk.
• Current evidence suggests biological plausibility but does not allow for generalizing an incontrovertible causal relationship to all patients and all autoimmune diseases.

Limitations of the evidence

It is important to distinguish between different types of evidence. Many of the cited results come from experimental studies in murine models or from molecular and mechanistic analyses that provide high biological plausibility but do not automatically prove that the same effect is identical in humans in all circumstances. Clinical observational studies report associations between high interferon activity or the presence of autoimmune disease and atherosclerosis phenomena, but associations are not proof of causality: confounding factors may coexist (e.g., medications, lifestyle, genetic characteristics). Furthermore, animal models used to investigate mechanisms do not always reproduce all the complexities of human disease, including comorbidities and treatments. Methodologically, much research is limited in size or focuses on specific cellular mechanisms; to move to clinical recommendations, well-designed clinical trials are needed to evaluate targeted interventions in identified human populations. Finally, individual variability (disease phenotypes, age, gender, medication use) necessitates caution in interpreting and applying the results [5][8].

Editorial conclusion

Recent research has clarified cellular and molecular components that can link the autoimmune response to the acceleration of atherosclerosis. Plasmacytoid dendritic cells and type I interferons emerge as key elements in this biological framework and offer concrete hypotheses for new research approaches. However, it remains necessary to evaluate with targeted clinical studies whether and how modulating these pathways improves cardiovascular outcomes in humans. In the meantime, careful management of cardiovascular risk factors remains the primary strategy for reducing risk in people with autoimmune diseases.

Editorial note

This article is derived from previously published content and has been updated following criteria of scientific accuracy and transparency. The primary sources used are listed in the "SCIENTIFIC RESEARCH" section. The article is informative: for clinical decisions and treatment, consult your doctor or specialist.

SCIENTIFIC RESEARCH

1. Plasmacytoid dendritic cells in atherosclerosis. Front Physiol. 2012;3:230. https://doi.org/10.3389/fphys.2012.00230
2. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation. 2012;125(13):1673–1683. https://doi.org/10.1161/CIRCULATIONAHA.111.046755
3. Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32(11):2569–2579. https://doi.org/10.1161/ATVBAHA.112.251314
4. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells drives pro-atherogenic T cell immunity. Circulation. 2014;130(16):1363–1373. https://doi.org/10.1161/CIRCULATIONAHA.114.011090
5. Type-I interferons in atherosclerosis. Int J Mol Sci. 2018; (review). https://doi.org/10.1155/2018/5906819
6. Role of interferon-alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase–related mechanisms. Am J Med Sci. 2014;348(2):168–175. https://doi.org/10.1097/MAJ.0000000000000284
7. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14:214–228. https://doi.org/10.1038/nrrheum.2018.31
8. The detrimental effects of interferon-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis. J Immunol. 2010;185(7):4457–4469. https://doi.org/10.4049/jimmunol.1001782